We are pulmonary hypertension professionals united in our vision for a world without pulmonary vascular disease. We believe we can achieve this together, and we won’t stop until we do.
PVRI 2025 Rio, Registration & abstract portals now live
Our PVRI 2025 Annual Congress, 'PVRI 2025 Rio: Embracing Heterogeneity', will be hosted at the Windsor Convention & Expo Centre. This year, our Congress will feature a Career Catalyst Luncheon: Speed Mentoring for Early Career PH Professionals, a Women in PH Luncheon, a Gala Dinner & Awards evening, and a series of pre-meetings.
Whether you’re a pulmonary hypertension specialist, a pharmaceutical or industry colleague, a regulator, a patient, or a caregiver, joining our growing global family means you share our vision to reduce the global burden of pulmonary vascular disease.
Held in the vibrant and captivating city of Rio de Janeiro at the Windsor Convention & Expo Centre, esteemed experts, healthcare professionals, and researchers from around the globe will converge to share groundbreaking insights, foster collaborations, and advance our collective mission towards conquering Pulmonary Vascular Diseases (PVDs). Registrations and abstract submissions are now open.
Patient focused webinar covering: When do I need to think about a lung transplant?, Transplant Evaluation, Listing and Surgery, What Can I expect after the transplant, A Patient’s Perspective: from two patients.
Webinar presentations: Cellular mechosignaling in pulmonary arterial hypertension; Sex differences in pulmonary arterial hypertension randomized clinical trials; Precapillary pulmonary hypertension and death from COVID-19; Estradiol and estrogen receptor protection of right ventricular function – role of apelin; Prostacyclin reverses right ventricular hypertrophy and dysfunction in severe PAH; Pulmonary vascular complications of heart failure with preserved ejection fraction
Webinar presentations: Autophagy and BMPR2 receptor degradation as the cause of PAH; BMPR1A promotes ID2-ZEB1 interaction to suppress endothelial to mesenchymal transition in PAH; Cardiovascular and pulmonary phenotypes for single and double knockout mice deficient in BMP9 and BMP10; BMPR2 – When and where the animal models match patient disease
Tricuspid annular plane systolic excursion (TAPSE) is usually measured with M-mode using sector line, however, this may not align with the anatomical shortening of the right ventricular (RV). In this study, we compared the different methods to measure TAPSE using three different reference lines (sector line, anatomical line, and apico-annular line).
Balloon pulmonary angioplasty (BPA) to treat chronic thromboembolic pulmonary hypertension (CTEPH) is generally reserved for distal obstruction precluding pulmonary endarterectomy (PEA) but can be used in patients with proximal disease who are at high surgical risk or refuse surgery. This single-center retrospective study compared BPA efficacy in patients with proximal versus distal CTEPH.
Treatment modalities for pulmonary arterial hypertension (PAH) improve quality of life and walk distance. However, none of these therapies alter the structural/functional pulmonary vascular integrity that results in vascular remodeling. PAH smooth muscle cells share biological characteristics with cancer cells, which may be potential therapeutic targets for PAH.
Abstract submissions for PVRI 2025 Rio: Embracing heterogeneity are now open! The best abstracts will be considered for travel awards. All accepted abstracts will be published in our journal, Pulmonary Circulation, and may appear on our website.
Congratulations to Joseph Newman, who was presented with the ELF Travel grant 10 September at the ERS Congress in Vienna for the best abstract in patient centred research entitled 'The Pulmonary Hypertension Global Patient Survey (PH GPS): an overview and results'.
The PVRI Innovative Drug Development Initiative (IDDI) Access to Care Workstream created the Access to Care poster which was presented at the PHA Conference in Indianapolis (15-18 August, 2024).
The purpose of the the Pulmonary Hypertension Association’s award is to support research aimed at addressing early diagnosis, education, and improving clinical outcomes and treatments for pulmonary hypertension (PH) patients who may be impacted by health inequities. Awards may be approved for up to a two (2) year period, up to $50,000/year.
